Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07005102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07005102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Lead sponsor
AbbVie
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 3, 2025
Completion date
November 30, 2036
Enrollment
854 (estimated)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

c-met, non-squamous non-small cell lung cancer